Prophylaxis of Organ Rejection Market Analysis, Size, Share, Growth, Trends And Forecast Opportunities

Global Prophylaxis of Organ Rejection Market is growing with factors such as the increased prevalence of organ transplantation, rise in surgical procedures, rise in recipient population and product launches. However, the factors that are expected to restrain the market are the rise in the cost of the transplantation procedure, lack of awareness about organ transplantation and the risks included while the patient receives the transplanted organ.

Get a Sample PDF of the report –

Global Prophylaxis of Organ Rejection Market Scenario

According to Data Bridge Market Research, the region which is dominating the global prophylaxis of organ rejection is North America. Astellas Pharma Inc. is dominating in North America, with a market share of 49.07%, since its major product prograf and advagraf (tacrolimus) are being used by transplant patients for organ rejection in North America.

In July 2021, Astellas Pharma Inc. had received the Food and Drug Administration (FDA) approval for prograf. Prograf is the drug which is being used to avoid rejection of new lung transplant. The approval received resulted in recommendation of prograf for use in liver, kidney and heart transplants to adult and paediatric patients

Now the question is which other regions is Astellas Pharma Inc. F. Hoffmann-La Roche Ltd and Bristol-Myers Squibb Company targeting? Data Bridge Market Research has estimated a large growth in North America. North America prophylaxis of organ rejection market and the market leaders targeting the U.S., Canada, and Mexico, to be their next pocket revenue for 2022.

Global prophylaxis of organ rejection market is becoming more competitive with companies such as Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company. These are the top dominating companies in prophylaxis of organ rejection market and are launching more new drugs for organ rejection in the market. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the global prophylaxis of organ rejection market.

The term prophylaxis means treatment given or action taken to prevent disease. The prophylaxis of organ rejection, refers to the prevention of organ rejection by use of medicines. The patients who undergo transplantation, must be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure graft survival. The transplant rejection is a process, in which a transplant recipient’s immunity the current rejection prophylaxis implements use of calcineurin inhibitors, mTOR inhibitors, antimetabolite agents, and corticosteroids. The treatment agents improve the short term consequences of the organ transplantation, but certain improvements. The recipient patients, who have undergone solid organ transplantation, should take anti-rejection medicines. This is because the immunity system would destroy the transplanted organ.

For more analysis on the global prophylaxis of organ rejection market request for a briefing with our analysts

Key Market Competitors Covered in the Report

Ossium Health, Inc.
Alphamab Oncology
Altavant Sciences, Inc.
Hansa Biopharma.
Concord Biotech
Panacea Biote
Accord-UK Ltd.
Veloxis Pharmaceuticals, Inc.
Astellas Pharma Inc.
Novartis AG
Bristol-Myers Squibb Company
Dr Reddy’s Laboratories, Ltd.
Viatris Inc.
Strides Pharma Science Limited.
Pfizer Inc.
Mayne Pharma Group Limited
Hikma Pharmaceuticals PLC
AbbVie Inc
Apotex Inc.
Teva Pharmaceutical U.S.A Inc.
Amneal Pharmaceuticals LLC.
Zydus Pharmaceuticals, Inc.
Novitium Pharma.
Hoffmann-La Roche Ltd
CSL Behring


In December 2021, Bristol-Myers Squibb Company, had received the Food and Drug Administration (FDA) approval for orencia (abatacept). Orencia (abatacept) is combined with a calcineurin inhibitor and methotrexate for the prevention of acute graft versus host disease (agvhd) in patients undergoing hematopoietic stem cell transplant. The approval received would make orencia (abatacept), become an important treatment option for prevention of liver rejection. The orencia (abatacept), would be able to fulfil the unmet medical need for organ rejection

In September 2020, F. Hoffmann-La Roche Ltd, had received the Food and Drug Administration (FDA) approval for BK virus quantitative test on cobas 6800/8800 Systems. The BK virus quantitative test, is used to provide optimum care for transplant patients. The approval received would improve the treatment plan for patients, undergoing organ transplantation. BK virus quantitative test can simultaneously monitor and improve care for transplant patients who are at risk for these common infections

Global prophylaxis of organ rejection market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Key Pointers Covered in This Market Research Report:
Market Size
Market New Sales Volumes
Market Replacement Sales Volumes
Installed Base
Market By Brands
Market Procedure Volumes
Market Product Price Analysis
Market Healthcare Outcomes
Market Cost of Care Analysis
Regulatory Framework and Changes
Prices and Reimbursement Analysis
Market Shares in Different Regions
Recent Developments for Market Competitors
Market Upcoming Applications
Market Innovators Study

This Report Consists of:
▪ No of pages: 350
▪ No of Figures: 60
▪ No of Tables: 220

Objectives of the Report
To carefully analyze and forecast the size of the market by value and volume.
To estimate the market shares of major segments of the
To showcase the development of the market in different parts of the world.
To analyze and study micro-markets in terms of their contributions to the market, their prospects, and individual growth trends.
To offer precise and useful details about factors affecting the growth of the
To provide a meticulous assessment of crucial business strategies used by leading companies operating in the market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches.

Destinations of This report:
1. To make accessible the wide-going outline of the market.
2. To accomplish the data about the central members in this industry, their item portfolios, and their key techniques.
3. To know about the future standpoint and possibilities for this market investigation and figure 2022-2029.
4. To dissect the market size of the market so that understanding the critical patterns from it gets simple.
5. To look at the market dependent on item, portion of the overall industry, and size of the item share.
6. To dissect possibilities or openings on the lookout for partners by realizing the high-development fragments of the market.
7. To increase bits of knowledge about the major provincial experiences in which the is prospering.
8. To accomplish delineations and gauge the market, as far as worth, by process, item type, and industry.
9. To strategically diagram the central parts and exhaustively dissect their market position as far as positioning and center capabilities, and detail the cutthroat scene for market pioneers.
10. To portray and estimate the market, as far as worth, for different fragments, by area North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW).

Report Coverage:
Vendor Profiles
Vendor Assessment
Technology Assessment
Product Mapping
Industry Outlook
Economic Analysis
Segmental Analysis
Market Size
Analysis Tables

Top Healthcare Reports:


Back to top button